Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Curatively resected HER2+ gastric or gastroesophageal junction adenocarcinoma; HER2+ status as defined by immunohistochemistry-2 positive or 3 positive with corroborative Fluorescence In Situ Hybridization+ result~* Participants with stages between Stage IB (T1N1M0) and Stage IIIC~* ECOG performance status score equal to or less than (\<=) 2 during screening~* Left ventricular ejection fraction equal to or higher than (\>=) 55% with acceptable levels of liver and renal functions~* No known contraindication to capecitabine, oxaliplatin, and trastuzumab~* No contraindication for radiotherapy or has not received any previous radiotherapy to the gastric region for any reason~Exclusion Criteria:~* Participants with a malign condition in the last 5 years except squamous cell carcinoma of the skin~* Previous neoadjuvant chemotherapy and/or radiotherapy~* Any disruption in the physical integrity of the upper gastrointestinal tract (except surgical intervention for gastric or gastroesophageal junction carcinoma)~* Known (previously diagnosed and ongoing) malabsorption syndrome~* Active gastrointestinal bleeding~* Participants with Stage IV gastric or gastroesophageal junction adenocarcinoma~* Clinically significant cardiac or cardiovascular disease~* Uncontrolled hypertension~* Participants who have received any investigational anti-cancer treatment or are being treated in a concomitant investigational drug study~* Abnormal laboratory values at screening for serum total bilirubin, alanine aminotransferase or aspartate amino transferase, alkaline phosphatase, absolute neutrophil count, platelet count, and/or hemoglobin~* Known or suspected hypersensitivity against trastuzumab or proteins of rodents~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).